Correction (DOI:10.1016/j.ahj.2007.04.010);No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: Insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial

American Heart Journal

Volumn 154, Issue 2, 2007, Pages 306-312

  Westerhout, Cynthia M ^a,b   Gnarpe, Judy ^a   Chang, Wei Ching ^a   FitzPatrick, Susan ^c   Barnathan, Elliot S ^c   Boersma, Eric ^b   Califf, Robert M ^d   Wallentin, Lars ^e   Simoons, Maarten L ^b   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CENTOCOR INC   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

EID: 34447578764     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.09.012     Document Type: Erratum

References (32)

1. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31 (1998) 1460-1465
2. Lindahl B., Toss H., Siegbahn A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 343 (2000) 1139-1147
3. James S.K., Armstrong P., Barnathan E., et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 41 (2003) 916-924
4. Kuo C.C., Shor A., Campbell L.A., et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 167 (1993) 841-849
5. Jackson L.A., Campbell L.A., Schmidt R.A., et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma. J Infect Dis 181 Suppl 3 (2000) S447-S448
6. Simoons M.L., and GUSTO IVA. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357 (2001) 1915-1924
7. Ottervanger J.P., Armstrong P., Barnathan E.S., et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) Trial. Circulation 107 (2003) 437-442
8. Hahn D.L., Golubjatnikov R., Hahn D.L., et al. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 12 (1992) 945-947
9. Gnarpe J., Sparr A., Naas J., et al. Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration. APMIS 108 (2000) 357-362
10. Gnarpe J., Gnarpe H., Gause-Nilsson I., et al. Seroprevalence of antibodies to Chlamydia pneumoniae in elderly people: a two-decade longitudinal and cohort difference study. Scand J Infect Dis 32 (2000) 177-179
11. Ridker P.M., Hennekens C.H., Buring J.E., et al. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 131 (1999) 573-577
12. Nieto F.J., Folsom A.R., Sorlie P.D., et al. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 150 (1999) 149-156
13. Ridker P.M., Kundsin R.B., Stampfer M.J., et al. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 99 (1999) 1161-1164
14. Wong B.Y., Gnarpe J., Teo K.K., et al. Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes. Am Heart J 144 (2002) 987-994
15. Cannon C.P., Braunwald E., McCabe C.H., et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 352 (2005) 1646-1654
16. Arcari C.M., Gaydos C.A., Nieto F.J., et al. Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military: the importance of timing of exposure measurement. Clin Infect Dis 40 (2005) 1123-1130
17. Strachan D.P., Carrington D., Mendall M.A., et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 318 (1999) 1035-1039
18. Siscovick D.S., Schwartz S.M., Corey L., et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 102 (2000) 2335-2340
19. Grayston J.T., Kronmal R.A., Jackson L.A., et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 352 (2005) 1637-1645
20. Muhlestein J.B., Anderson J.L., Carlquist J.F., et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102 (2000) 1755-1760
21. Neumann F., Kastrati A., Miethke T., et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357 (2001) 2085-2089
22. Sinisalo J., Mattila K., Valtonen V., et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 105 (2002) 1555-1560
23. Zahn R., Schneider S., Frilling B., et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 107 (2003) 1253-1259
24. Cercek B., Shah P.K., Noc M., et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 361 (2003) 809-813
25. O'Connor C.M., Dunne M.W., Pfeffer M.A., et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290 (2003) 1459-1466
26. Witherell H.L., Smith K.L., Friedman G.D., et al. C-reactive protein, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus and risk for myocardial infarction. Ann Epidemiol 13 (2003) 170-177
27. Wong B.Y., and Gnarpe J. Chlamydia pneumoniae and acute coronary syndrome. N Engl J Med 353 (2005) 525-528
28. Tiran A., Gruber H.J., Graier W.F., et al. Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler Thromb Vasc Biol 22 (2002) 1075-1080
29. 2 synthesis and attenuates chlamydial growth. Int J Med Microbiol 52 (2003) 409-415
30. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
31. Zhu J., Quyyumi A.A., Norman J.E., et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 85 (2000) 140-146
32. Zhu J., Nieto F.J., Horne B.D., et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 103 (2001) 45-51